Filing Flows › ANI Pharmaceuticals (ANIP) › Generics and Other total net revenues revenue
ANI Pharmaceuticals (ANIP) Generics and Other total net revenues revenue by quarter
ANI Pharmaceuticals' Generics and Other total net revenues revenue was $108M in Q3 2026 (third quarter 2026), +8% from Q2 2026. Over the last 7 quarters it ranged from $94.2M (Q2 2025) to $109M (Q1 2026).
| Quarter | Generics and Other total net revenues revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $108M | +8% | +10% |
| Q2 2026 | $101M | -8% | +7% |
| Q1 2026 | $109M | +6% | +6% |
| Q4 2025 | $103M | +5% | — |
| Q3 2025 | $98.7M | +5% | — |
| Q2 2025 | $94.2M | -9% | — |
| Q1 2025 | $103M | — | — |
Q3 2026 at a glance
ANI Pharmaceuticals, Q3 2026: revenue $291M (+28% year over year), operating margin 18.0%, net earnings $35.1M, operating cash flow $83.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is ANI Pharmaceuticals' Generics and Other total net revenues revenue?
ANI Pharmaceuticals' Generics and Other total net revenues revenue was $108M in Q3 2026 (third quarter 2026), +8% from Q2 2026.
How has ANI Pharmaceuticals' Generics and Other total net revenues revenue changed?
Over the last 7 quarters it ranged from $94.2M (Q2 2025) to $109M (Q1 2026).